The Compounding Chemotherapy Market is gaining momentum as personalized cancer treatment creates demand for medications prepared according to individual patient needs. The market was valued at USD 8.84 billion in 2023 and USD 9.48 billion in 2024, with revenue forecast to reach USD 16.5 billion by 2032.

One of the strongest technology trends is the adoption of automated compounding equipment. Robotic systems and automated dosing platforms can help pharmacists handle hazardous medicines with greater process control while supporting accurate preparation and documentation.

Applications extend across oncology, pediatric treatment, pain management, and supportive cancer care. Injectable and infusion compounds are particularly relevant in hospital settings, while oral preparations and specialty pharmacy services provide additional options for patients requiring customized therapy.

Regional demand is supported by established cancer-care infrastructure in North America and Europe. Asia-Pacific is emerging as an important growth area because of increasing cancer incidence, expanding oncology facilities, and greater investment in specialized healthcare services.

The market has room for further development through smart pharmacy systems, automated dose verification, centralized compounding facilities, and improved hazardous-drug handling. These solutions can help healthcare organizations manage increasing chemotherapy workloads while maintaining stringent safety standards.